ANZUPGO (delgocitinib)
ANZUPGO is a topical medication that treats adults with moderate to severe chronic hand eczema. It helps patients who have not seen enough improvement with topical corticosteroids or for whom those treatments are not recommended. To ensure safety, this therapy should not be used in combination with other JAK inhibitors or potent immunosuppressants.
How ANZUPGO Works
This medication works by inhibiting the activity of Janus kinase enzymes, specifically JAK1, JAK2, JAK3, and TYK2. By blocking these targets, the drug prevents the activation and movement of signaling proteins into the cell nucleus, which stops the expression of certain genes.
Development Insights
Details
- Status
- Prescription
- First Approved
- 2025-07-23
- Patent Cliff
- 2031
- Routes
- TOPICAL
- Dosage Forms
- CREAM
ANZUPGO Approval History
What ANZUPGO Treats
1 indicationsANZUPGO is approved for 1 conditions since its original approval in 2025. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Chronic Hand Eczema
ANZUPGO Target & Pathway
ProTarget
A member of the JAK family involved in signaling for interferons and several interleukins. JAK1 inhibition is effective in rheumatoid arthritis, atopic dermatitis, and other inflammatory conditions by blocking multiple cytokine pathways.
ANZUPGO Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
MoA expansion candidates
Same target(s), different indications — where else is this mechanism being explored?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Clinical Trial Registry
8 trials| Trial | Sponsor ID | Phase | Status | Title |
|---|---|---|---|---|
| NCT07487948 | STUDY-26-00103 | Ph 2 | recruiting | Safety and Biomarker Responses of Delgocitinib (JAK1,2,3/TYK2 Inhibitor) in Central Centrifugal Cicatricial Alopecia and Lichen Planopilaris |
| NCT05355818 DELTA TEEN results posted | LP0133-1426 2021-006340-27, U1111-1284-2122 | Ph 3 | completed | Efficacy and Safety of Delgocitinib Cream in Adolescents 12-17 Years of Age With Moderate to Severe Chronic Hand Eczema |
| NCT07335588 DELTA CARE 1 | LP0133-2395 2025-524873-17-00, U1111-1333-1675 | Ph 3 | not yet recruiting | A 52-Week Trial to Investigate the Efficacy and Safety of Delgocitinib Cream in Adult Participants With Lichen Sclerosus |
| NCT06004050 | LP0133-2283 | Ph 3 | completed | A Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Delgocitinib Cream in Chinese Adults and Adolescents With Moderate to Severe Chronic Hand Eczema |
| NCT05259722 DELTA FORCE results posted | LP0133-1528 2021-003543-16, U1111-1284-2242 | Ph 3 | completed | A 24 Week Trial to Compare the Efficacy and Safety of Delgocitinib Cream 20 mg/g Twice-daily With Alitretinoin Capsules Once-daily in Adult Participants With Severe Chronic Hand Eczema |
| NCT04949841 DELTA 3 results posted | LP0133-1403 2020-002962-15, U1111-1284-2216 | Ph 3 | completed | Open-label Multi-site Extension Trial in Subjects Who Completed the DELTA 1 or DELTA 2 Trials |
| NCT05486117 | LP0133-2285 2022-000782-40, U1111-1284-2254 | Ph 1 | completed | Pharmacokinetics of Delgocitinib 20 mg/g Cream in Subjects With Chronic Hand Eczema |
| NCT03826901 | LP0133-1181 | Ph 1 | completed | Delgocitinib Cream for the Treatment of Moderate to Severe Atopic Dermatitis During 8 Weeks in Adults, Adolescents, and Children |
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
ANZUPGO FDA Label Details
Indications & Usage
FDA Label (PDF)ANZUPGO is indicated for the treatment of Chronic Hand Eczema.
ANZUPGO Patents & Exclusivity
Patents (1 active)
Exclusivity
Pro Intelligence Preview
Deep insights for ANZUPGO
Revenue Insights
- • Quarterly revenue tracking
- • Historical trend analysis
Patent Timeline
- • Cliff: 2031
- • 1 active patents
Trial Analysis
- • 8 total trials
- • Stage: Stable
Competitive Landscape
- • Competitor tracking
- • Same target/indication analysis
Full approval history • All patents • Revenue trends • Competitor analysis
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.
How We Calculate These Metrics
Trial Activity Stage
Measures the current development activity pattern based on trial phases, status, and trends. Important: This measures R&D activity, not commercial lifecycle.
Trial statuses: "Active" means recruiting or ongoing. "Completed" means reached planned endpoint. "Terminated" means stopped early—often due to safety, efficacy, or business reasons.
- Growth: High proportion of early-phase trials (Phase 1/2), active development
- Expansion: Significant Phase 3 activity, approaching or pursuing approvals
- Mature: Substantial Phase 4 post-marketing studies
- Stable: Mixed phase distribution, steady development
- Declining: Low active trial ratio, reduced R&D investment